Defiance Next Gen Altered Experience (PSY) ETF Holdings & Analysis

What PSY does

This fund is designed to mirror a systematically constructed index. This index evaluates the performance of companies engaged in specific, legally authorized activities, always in adherence to national laws. These activities encompass the fields of medical psychedelics, therapeutic cannabis, cannabis-derived pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine. To achieve its financial goals, the fund utilizes a full replication approach, meaning it directly invests in all the constituent securities of the underlying index, striving to maintain their proportional weightings. It functions as a non-diversified investment product.

Fund profile

Top holdings

Sector allocation

Geographic allocation

PortView Portfolio Insights

PortView analyzes how PSY fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Related securities

Related stocks

Frequently asked questions

What does PSY track?

PSY is the Defiance Next Gen Altered Experience ETF, a Other ETF.

What is the expense ratio of PSY?

Expense ratio data for PSY is shown on the page when available from our data provider.

What are the largest holdings in PSY?

Top holdings include Cash&Other, 1914272D.TO.

How can PortView analyze PSY overlap with other ETFs?

PortView computes the holdings overlap between PSY and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.